Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Berk

Showing results (91-100 of 121) with videos related to

Pageof 13
Sort By:
Journal of Drugs in Dermatology : JDD|January 11, 2018
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL TrialLeon H Kircik, Janet DuBois, Zoe Diana Draelos, et al.
Dermatology and Therapy|July 8, 2021
The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area ScoreKim A Papp, Mark G Lebwohl, Leon H Kircik, et al.
Pediatric Dermatology|July 9, 2010
Re: Propranolol treatment for hemangioma of infancy: risks and recommendationsSusan J Bayliss, David R Berk, George F Van Hare, et al.
The Journal of Clinical and Aesthetic Dermatology|November 17, 2016
Efficacy, Safety, and Dermal Tolerability of Dapsone Gel, 7.5% in Patients with Moderate Acne Vulgaris: A Pooled Analysis of Two Phase 3 TrialsDiane M Thiboutot, Leon Kircik, Amy McMichael, et al.
Pediatric Dermatology|April 22, 2011
Acanthosis nigricans and hypochondroplasia in a child with a K650Q mutation in FGFR3David R Berk, Maria Del Carmen Boente, Daniela Montanari, et al.
Journal of Drugs in Dermatology : JDD|July 8, 2017
Treatment Response With Once-Daily Topical Dapsone Gel, 7.5% for Acne Vulgaris: Subgroup Analysis of Pooled Data from Two Randomized, Double-Blind StuZoe Diana Draelos, David A Rodriguez, Steven E Kempers, et al.
American Journal of Human Genetics|August 28, 2012
Genomic profiling of a human organotypic model of AEC syndrome reveals ZNF750 as an essential downstream target of mutant TP63Brian J Zarnegar, Dan E Webster, Vanessa Lopez-Pajares, et al.
Journal of the American Academy of Dermatology|February 8, 2018
Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trialZoe Diana Draelos, Michael H Gold, Robert A Weiss, et al.
Journal of Drugs in Dermatology : JDD|May 12, 2016
Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled TrialsLinda F Stein Gold, Michael T Jarratt, Alicia D Bucko, et al.
JAMA|May 12, 2005
Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohortDavid R Berk, Meira S Falkovitz-Halpern, David W Hill, et al.
Pageof 13

Showing results (91-100 of 121) with videos related to

Sort By:
Pageof 13
Journal of Drugs in Dermatology : JDD|January 11, 2018
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL TrialLeon H Kircik, Janet DuBois, Zoe Diana Draelos, et al.
Dermatology and Therapy|July 8, 2021
The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area ScoreKim A Papp, Mark G Lebwohl, Leon H Kircik, et al.
Pediatric Dermatology|July 9, 2010
Re: Propranolol treatment for hemangioma of infancy: risks and recommendationsSusan J Bayliss, David R Berk, George F Van Hare, et al.
The Journal of Clinical and Aesthetic Dermatology|November 17, 2016
Efficacy, Safety, and Dermal Tolerability of Dapsone Gel, 7.5% in Patients with Moderate Acne Vulgaris: A Pooled Analysis of Two Phase 3 TrialsDiane M Thiboutot, Leon Kircik, Amy McMichael, et al.
Pediatric Dermatology|April 22, 2011
Acanthosis nigricans and hypochondroplasia in a child with a K650Q mutation in FGFR3David R Berk, Maria Del Carmen Boente, Daniela Montanari, et al.
Journal of Drugs in Dermatology : JDD|July 8, 2017
Treatment Response With Once-Daily Topical Dapsone Gel, 7.5% for Acne Vulgaris: Subgroup Analysis of Pooled Data from Two Randomized, Double-Blind StuZoe Diana Draelos, David A Rodriguez, Steven E Kempers, et al.
American Journal of Human Genetics|August 28, 2012
Genomic profiling of a human organotypic model of AEC syndrome reveals ZNF750 as an essential downstream target of mutant TP63Brian J Zarnegar, Dan E Webster, Vanessa Lopez-Pajares, et al.
Journal of the American Academy of Dermatology|February 8, 2018
Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trialZoe Diana Draelos, Michael H Gold, Robert A Weiss, et al.
Journal of Drugs in Dermatology : JDD|May 12, 2016
Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled TrialsLinda F Stein Gold, Michael T Jarratt, Alicia D Bucko, et al.
JAMA|May 12, 2005
Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohortDavid R Berk, Meira S Falkovitz-Halpern, David W Hill, et al.
Pageof 13